Obermatt
See Similar Stocks →

Bayer

GER:BAYN · DE000BAY0017
PharmaceuticalsXX-Large

360

15
EV / EBIT69
Price / Owner Earnings97
Owner Earnings Yield1
Dividend Yield51
Price/Sales93
EV / Gross Profit93
Price/Book86
Return on Capital19
Cash Return on Capital4
Return on Equity5
EBIT Margin20
Gross Profitability22
Accruals90
Owner Earnings Margin4
Sales growth24
Profit Growth88
Long-Term EPS Growth52
Reinvestment43
Price momentum71
Debt load9
Refinancing70
Debt Payback1
Liquidity24
Analyst ratings51
Opinion Changes50
Price Target Upside90
Market mood1
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Bayer doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryGermany
IndustryPharmaceuticals
SizeXX-Large
TypePublic Company
ExchangeXTRA
Founded1952
Employees65,994
Websitebayer.com
ISINDE000BAY0017
Last UpdateApr 2, 2026
Indices
CDAX (Germany)DAX 40 (Germany)EURO STOXX 50 (European Union)
Themes
Health DiagnosticsHematologyPain ManagementWomen's HealthAllergyOphthalmologyGeneticsCardiovascularOncologyAssociationConsumer ElectronicsPharmaceutical

Description

Bayer Aktiengesellschaft operates as a life science company that focus on healthcare and agriculture sectors. The company develops prescription medications tailored for significant therapeutic areas, such as cardiology, women's health, oncology, and…

Analysis

Weak and unloved

Bayer Aktiengesellschaft scores below average on quality and is priced accordingly, a low-conviction position in either direction.

Valuation data is not available for this company.

Growth is tepid; the safety picture is fragile. The company scores 6/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
43
2023202420252026

All-time high

43

Jun 2026

All-time low

1

Apr 2024

Average rank

14

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
93
97
86
75
Price/Earnings
76
100
97
93
Price/Book
86
97
88
67
Dividend Yield
51
26
27
86
Value (overall)
91
90
100
97

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Bayer with its peers
Haleon
LSE:HLN
31
CountryUK
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Perrigo
NYQ:PRGO
8
CountryIreland
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Novartis
VTX:NOVN
38
CountrySwitzerland
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Sanofi India
NSI:SANOFI
56
CountryFrance
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Faes Farma
MCE:FAE
44
CountrySpain
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
GlaxoSmithKline Pharmaceuticals
NSI:GLAXO
53
CountryUK
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →